January 22, 2019

LORNOXICAM DRUG PROFILE PDF

Lornoxicam is a non-steroidal anti-inflammatory drug of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It is available in oral and. Lornoxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory. Lornoxicam is a nonsteroidal anti-inflammatory drug with analgesic properties From: Profiles of Drug Substances, Excipients and Related Methodology,

Author: Akinor Kazralkis
Country: Saudi Arabia
Language: English (Spanish)
Genre: Photos
Published (Last): 2 March 2010
Pages: 184
PDF File Size: 11.44 Mb
ePub File Size: 9.30 Mb
ISBN: 998-9-42960-257-6
Downloads: 11017
Price: Free* [*Free Regsitration Required]
Uploader: Shagis

Chromic citrate Lornoxicam may decrease the excretion rate of Chromic citrate which could result in a higher serum level. Enasidenib The metabolism of Lornoxicam can be decreased when combined with Enasidenib.

Bemiparin The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Bemiparin. Cyclizine The metabolism of Lornoxicam can be decreased when combined with Cyclizine.

Lornoxicam Drug Information – Indications, Dosage, Side Effects and Precautions

Capecitabine The metabolism of Lornoxicam can be decreased when combined with Capecitabine. Delavirdine The metabolism of Lornoxicam can be decreased when combined with Delavirdine. Dihydralazine The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Lornoxicam. Ganciclovir Lornoxicam may decrease the excretion rate of Ganciclovir which could result in a higher serum level.

Eucalyptus oil Lornoxicam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Chloral hydrate Lornoxicam may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Fenoterol The lirnoxicam or severity of hypertension can be increased when Fenoterol is combined with Lornoxicam.

Most Related  TECNICA DE ASPIRACION DE SECRECIONES PDF

Mean elimination half life of hours.

Amphetamine Lornoxicam may decrease the excretion rate of Amphetamine which could result in a higher serum crug. Fluproquazone Proquazone ; Aminonicotinic acids: The effect of diureticsACE inhibitors and angiotensin II receptor antagonists can be reduced, but this is only relevant in patients with special risks like heart failure.

Lornoxicam | C13H10ClN3O4S2 – PubChem

Lynestrenol The metabolism of Lynestrenol can be decreased when combined with Lornoxicam. Bekanamycin The risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Bekanamycin.

Dexpanthenol Lornoxicam may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Isavuconazole The metabolism of Lornoxicam can be increased when combined with Isavuconazole.

Lornoxicam information from DrugsUpdate

Betamethasone phosphate The risk or severity of gastrointestinal irritation can be increased when Betamethasone phosphate is combined with Lornoxicam. Linsidomine The therapeutic efficacy of Linsidomine can be decreased when used in combination with Lornoxicam. Betrixaban The risk or severity of bleeding can profjle increased when Betrixaban is combined with Lornoxicam. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins act as messenger molecules in the process of inflammation and thromboxane from arachidonic acid.

Lornoxicam

Lonazolac The risk or severity of adverse effects can be increased when Lornoxicam is combined with Lonazolac. Magnesium chloride Lornoxicam may decrease the excretion rate of Magnesium chloride which could result in a oornoxicam serum level.

Most Related  2SK3919 PDF

Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Lornoxicam. Lab interference Information Not Available. Ceftobiprole The risk or severity of nephrotoxicity can be increased when Ceftobiprole is combined with Lornoxicam.

Eletriptan The metabolism of Lornoxicam can be decreased when combined with Eletriptan. Alprenolol Lornoxicam may decrease the antihypertensive activities of Alprenolol. Agomelatine The metabolism of Lornoxicam can be decreased when combined with Agomelatine.

Azilsartan medoxomil The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Lornoxicam. Alminoprofen The risk or severity of adverse effects can be increased when Lornoxicam lornosicam combined with Alminoprofen.

Florbetapir 18F Lornoxicam may decrease the excretion rate of Florbetapir 18F which could result in a higher serum level. Isoxsuprine The risk or severity of hypertension can be increased when Lornoxicam is combined with Isoxsuprine.

Abediterol The risk or severity of hypertension can be increased when Lornoxicam is combined with Abediterol. Ifenprodil The risk or severity of prodile can be increased when Lornoxicam is combined with Ifenprodil. Eperisone The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Eperisone.